Teva Pharmaceutical Industries Ltd.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-49.0M | $-206.0M | $157.0M | $24.0M |
| Jun 2022 | $123.0M | $-4.0M | $127.0M | $39.0M |
| Sep 2022 | $543.0M | $421.0M | $122.0M | $26.0M |
| Mar 2023 | $-145.0M | $-284.0M | $139.0M | $32.0M |
| Jun 2023 | $324.0M | $205.0M | $119.0M | $30.0M |
| Sep 2023 | $5.0M | $-144.0M | $149.0M | $31.0M |
| Mar 2024 | $-124.0M | $-248.0M | $124.0M | $28.0M |
| Jun 2024 | $103.0M | $6.0M | $97.0M | $32.0M |
| Sep 2024 | $693.0M | $545.0M | $148.0M | $29.0M |
| Mar 2025 | $-105.0M | $-232.0M | $127.0M | $34.0M |
| Jun 2025 | $227.0M | $131.0M | $96.0M | $38.0M |
| Sep 2025 | $369.0M | $233.0M | $136.0M | $34.0M |
| Mar 2026 | $-40.0M | $-208.0M | $168.0M | $43.0M |
| Jun 2026 | $411.0M | $307.0M | $104.0M | $40.0M |